TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to measure the effects of an enhanced service where a pharmacists is part of the healthcare team on the ward (focusing on drug-related problems and transferring information between primary and secondary care). Primary outcome measure is visits to hospital during a 12-month follow-up period, and the population is patients 80 years and older.


Options:
A: Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal intervention | Arm Label: Enhanced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Minimal intervention; Assigned to Arm(s): Minimal intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced intervention
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
C: Arm Label: SHHE Peridischarge intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SHHE Peridischarge Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SHHE Peridischarge Intervention; Assigned to Arm(s): SHHE Peridischarge intervention
D: Intervention Type: PROCEDURE; Name: structured therapeutic chain of stroke treatment; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to measure the effects of an enhanced service where a pharmacists is part of the healthcare team on the ward (focusing on drug-related problems and transferring information between primary and secondary care). Primary outcome measure is visits to hospital during a 12-month follow-up period, and the population is patients 80 years and older.


Options:
A: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A
B: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing
C: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to measure the effects of an enhanced service where a pharmacists is part of the healthcare team on the ward (focusing on drug-related problems and transferring information between primary and secondary care). Primary outcome measure is visits to hospital during a 12-month follow-up period, and the population is patients 80 years and older.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
B: Arm Label: Application of STOPP/START criteria; Type: ACTIVE_COMPARATOR; Interventions: Other: Application of STOPP/START criteria | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Normal pharmaceutical care | Intervention Type: OTHER; Name: Application of STOPP/START criteria; Assigned to Arm(s): Application of STOPP/START criteria | Intervention Type: OTHER; Name: Normal pharmaceutical care; Assigned to Arm(s): Control
C: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing
D: Arm Label: Shed-Meds: A Patient-Centered Deprescribing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Shed-Meds: A Patient-Centered Deprescribing Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shed-Meds: A Patient-Centered Deprescribing Intervention; Assigned to Arm(s): Shed-Meds: A Patient-Centered Deprescribing Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to measure the effects of an enhanced service where a pharmacists is part of the healthcare team on the ward (focusing on drug-related problems and transferring information between primary and secondary care). Primary outcome measure is visits to hospital during a 12-month follow-up period, and the population is patients 80 years and older.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
B: Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal intervention | Arm Label: Enhanced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Minimal intervention; Assigned to Arm(s): Minimal intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced intervention
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2
D: Arm Label: SHHE Peridischarge intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SHHE Peridischarge Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SHHE Peridischarge Intervention; Assigned to Arm(s): SHHE Peridischarge intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy
Brief Summary: Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: Rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosiglitazone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Rosiglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)
Brief Summary: This is a multi-center trial to test safety and evaluate early treatment intervention with valproic acid and carnitine in moderating SMA symptoms of Type I infants.


Options:
A: N/A
B: Arm Label: Olesoxime; Type: EXPERIMENTAL; Interventions: Drug: Olesoxime | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olesoxime; Assigned to Arm(s): Olesoxime | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): 1
D: Arm Label: Nusinersen 6 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Nusinersen 12 mg; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): Nusinersen 12 mg, Nusinersen 6 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Haemodialysis Patients With Chronic Renal Anaemia.
Brief Summary: This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia. Patients will receive 4-weekly intravenous injections of Mircera, at a starting dose of 120, 200 or 360 micrograms. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia
B: Arm Label: RO0503821 (C.E.R.A.), 1x/4weeks; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (C.E.R.A.), 1x/4weeks
C: Arm Label: C.E.R.A. 120, 200, or 360 mcg; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A. 120, 200, or 360 mcg
D: Arm Label: Methoxy Polyethylene Glycol-epoetin Beta; Type: EXPERIMENTAL; Interventions: Drug: Methoxy Polyethylene Glycol-epoetin Beta | Arm Label: Epoetin Beta or Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Beta, Drug: Darbepoetin Alfa | Intervention Type: DRUG; Name: Methoxy Polyethylene Glycol-epoetin Beta; Assigned to Arm(s): Methoxy Polyethylene Glycol-epoetin Beta | Intervention Type: DRUG; Name: Epoetin Beta; Assigned to Arm(s): Epoetin Beta or Darbepoetin Alfa | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Epoetin Beta or Darbepoetin Alfa

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Occlusion Prevention for Trabeculectomy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study)
Brief Summary: The purpose of the study is to study the safety of the combination of ranibizumab and MMC vs monotherapy MMC vs intravitreal ranibizumab injection in patients with glaucoma.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): B
B: Arm Label: Ranibizumab alone; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab and MMC; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab and MMC | Arm Label: MMC alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: MMC | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab alone | Intervention Type: DRUG; Name: Ranibizumab and MMC; Assigned to Arm(s): Ranibizumab and MMC | Intervention Type: DRUG; Name: MMC; Assigned to Arm(s): MMC alone
C: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
D: Arm Label: Paclitaxel + Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, Drug: Paclitaxel | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel, Paclitaxel + Bevacizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIA Study of Subcutaneous 5-aza-2'- Deoxycytidine (Decitabine) in Patients With Thalassemia Intermedia
Brief Summary: Thalassemia intermedia (TI) is an inherited blood disorder that can cause anemia due to low levels of hemoglobin. Decitabine is a medication that may be effective at increasing hemoglobin levels. This study will evaluate the safety and effectiveness of decitabine at increasing hemoglobin levels in people with TI.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Decitabine (USAN, INN) | Intervention Type: DRUG; Name: Decitabine (USAN, INN); Assigned to Arm(s): 1
B: Arm Label: research; Type: N/A; Interventions: Drug: Yisuishengxue Granule | Arm Label: clinical research; Type: N/A; Interventions: Drug: Yisuishengxue Granule | Intervention Type: DRUG; Name: Yisuishengxue Granule; Assigned to Arm(s): clinical research, research
C: Arm Label: Hydroxyurea,blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydroxyurea, blood transfusion | Arm Label: Hydroxyurea, Epiao; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea ,Epiao | Intervention Type: DRUG; Name: Hydroxyurea ,Epiao; Assigned to Arm(s): Hydroxyurea, Epiao | Intervention Type: DRUG; Name: hydroxyurea, blood transfusion; Assigned to Arm(s): Hydroxyurea,blood transfusion
D: Arm Label: HQK-1001; Type: ACTIVE_COMPARATOR; Interventions: Drug: HQK-1001 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HQK-1001; Assigned to Arm(s): HQK-1001 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Longitudinal Cohort Study of Patients With Thalassemia in the Thalassemia Clinical Research Network
Brief Summary: Thalassemias are inherited blood disorders that can cause anemia and other health problems. The goal of this study is to collect information on complications of the disease among people who currently have or previously had thalassemia.


Options:
A: Arm Label: Thalassemia cohort; Type: N/A; Interventions: N/A | Arm Label: Successful SCT cohort; Type: N/A; Interventions: N/A
B: Arm Label: arm 1 iron chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone | Arm Label: arm 2 blood transfusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Deferiprone | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): arm 1 iron chelation, arm 2 blood transfusion
C: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
D: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Longitudinal Cohort Study of Patients With Thalassemia in the Thalassemia Clinical Research Network
Brief Summary: Thalassemias are inherited blood disorders that can cause anemia and other health problems. The goal of this study is to collect information on complications of the disease among people who currently have or previously had thalassemia.


Options:
A: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
C: Arm Label: Thalassemia cohort; Type: N/A; Interventions: N/A | Arm Label: Successful SCT cohort; Type: N/A; Interventions: N/A
D: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Weight Loss Technologies for Weight and Blood Pressure Control in Urban Clinics
Brief Summary: Obesity is a serious health problem that is a contributing factor for heart disease and high blood pressure. This study will evaluate a lifestyle modification program that aims to encourage weight loss and improve the health of people with high blood pressure from low income and minority communities.


Options:
A: Intervention Type: BEHAVIORAL; Name: Mammography appointment reminders; telephone counseling; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: QuitLink (office support system for quit line referral); Assigned to Arm(s): N/A
C: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care and Reading Materials | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Modification Program | Intervention Type: BEHAVIORAL; Name: Lifestyle Modification Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Usual Care and Reading Materials; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Tolerance and Metabolic Effects of Using a Preoperative Oral Nutritional Supplement (PreOP Booster) in Gastrointestinal Surgery
Brief Summary: The aim of this pilot study is to obtain data on the safety, tolerance and metabolic effects of the oral nutritional supplement (PreOP Booster) given to patients prior to gastrointestinal surgery.


Options:
A: Arm Label: Aminolaban EN; Type: EXPERIMENTAL; Interventions: Drug: Aminoleban EN | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Drug: Aminoleban EN | Intervention Type: DRUG; Name: Aminoleban EN; Assigned to Arm(s): Aminolaban EN, Control
B: Arm Label: Test; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOP Booster (oral nutritional supplement, food for special medical purposes); Assigned to Arm(s): Control, Test
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard ERAS group | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide), Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Intervention Type: DRUG; Name: Post operative laxation (Magnesium Oxide); Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative metabolic conditioning postoperative nutritional supplementation; Assigned to Arm(s): 3, 4 | Intervention Type: OTHER; Name: Standard ERAS group; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Traditional management | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fast track patient management | Intervention Type: PROCEDURE; Name: Fast track patient management; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Traditional management; Assigned to Arm(s): A

Answer: B